Osimertinib (Tagrisso), at 160 mg daily, demonstrated efficacy in the central nervous system (CNS) and a manageable safety profile in patients with EGFR
-mutant advanced non–small cell lung cancer (NSCLC) who have leptomeningeal metastases (LMs), according to results of the phase I BLOOM trial.
mutations (exon 19 deletions or exon 21 L858R substitution mutations).
Yang JCH, Kim SW, Kim DW, et al. Osimertinib in patients with epidermal growth factor receptor mutation–positive non–small-cell lung cancer and leptomeningeal metastases: the BLOOM study. J Clin Oncol. 2019;38(6):538-548, doi: 10.1200/JCO.19.00457.
... to read the full story